Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Cytokinetics Inc (CYTK) vs Google Inc (GOOG) Price & Performance

Cytokinetics IncTrade
Google IncTrade

Price performance (Past 24H)

Key statistics

Cytokinetics Inc vs Google Inc — how do they compare? Cytokinetics Inc trades at $76.73 (market cap $10.63B), while Google Inc trades at $340.04 (market cap $4.20T). The key difference: Google Inc is far larger — about 395.1× Cytokinetics Inc's market cap, and Google Inc pays a 0.26% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals.

CYTKGOOG
Market Cap
$10.63B$4.20T
Sector
TechnologyTechnology
52-Week High
$87.26$399.06
52-Week Low
$34.31$200.19
Enterprise Value
$10.74B$4.09T
Volume
1,511,127
Dividend Yield
0.26%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Cytokinetics Inc

CYTK trades at $77.07, down 0.54% on the day, with a bearish technical signal from moving averages. The company reported a Q2 2026 loss of $1.50 per share, beating estimates, but revenue of $68 million in 2026 reflects a net loss margin of -1,321.12%. Recent UK approval for MYQORZO and positive NICE guidance provide commercial momentum, yet high SG&A costs and negative cash flow from operations highlight ongoing financial strain.

The outlook hinges on MYQORZO's commercial execution and label expansion, with a consensus price target of $111.14 implying 44% upside. Risks include sustained cash burn, competitive pressure, and reliance on aficamten's clinical success. Analyst sentiment is overwhelmingly bullish, but profitability remains distant.

Google Inc

Alphabet (GOOG) trades at $340.22, down 4.39% over 24 hours, with a bearish technical signal from moving averages but neutral oscillators. The stock shows strong fundamentals, with revenue growing from $282.8B in 2022 to $402.84B in 2025 and net income margin expanding to 32.8%. Recent earnings beats and a consensus analyst price target of $431.67 suggest upside potential, though high capital expenditure plans and regulatory scrutiny pose risks.

The outlook remains positive due to robust AI adoption, with Gemini reaching 1 billion users, but investors face headwinds from elevated capex and antitrust investigations. Wall Street sentiment is overwhelmingly bullish, with 86.84% of analysts rating it a buy, highlighting growth prospects amid competitive and regulatory challenges.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Cytokinetics Inc

Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.

Read more on CYTK

About Google Inc

Alphabet Inc. operates as a holding company. The Company, through its subsidiaries, provides web-based search, advertisements, maps, software applications, mobile operating systems, consumer content, enterprise solutions, commerce, and hardware products.

Read more on GOOG